VIR Jul 2024 17.500 call
- Zacks
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
SAN FRANCISCO, April 18, 2024--Vir Biotechnology, Inc. ("Vir" or "the Company", Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the "Board") at its upcoming annual meeting of stockholders on May 29, 2024 (the "Annual Meeting"). If elected, each of Drs. Bischofberger and Farid will join the Board on such date.
- Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO, April 11, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
